Malaysia vs Yemen: Average cost of multi drug-resistant tuberculosis treatment
Malaysia
2,000 constant 2022 US$
in 2024
Yemen
2,510 constant 2022 US$
in 2024
Malaysia rank
22nd
Yemen rank
20th
Average cost of multi drug-resistant tuberculosis treatment over time
- Malaysia
- Yemen
How they compare
Yemen currently reports 2,510 constant 2022 US$ against 2,000 constant 2022 US$ in Malaysia, a difference of 510 constant 2022 US$.
That makes Yemen's figure about 1.3 times Malaysia's.
Across all 7 years both countries report, Yemen has been ahead every year.
Malaysia ranks 22nd and Yemen ranks 20th of 92 countries.
Yemen has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malaysia | Yemen | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,000 constant 2022 US$ | 2,720 constant 2022 US$ | 720 constant 2022 US$ | Yemen |
| 2020s | 2,000 constant 2022 US$ | 3,052 constant 2022 US$ | 1,052 constant 2022 US$ | Yemen |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Malaysia or Yemen?
- Yemen, at 2,510 constant 2022 US$ against 2,000 constant 2022 US$ in Malaysia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Malaysia and Yemen?
- 510 constant 2022 US$, with Yemen ahead.
- How many years of comparable data are there for Malaysia and Yemen?
- 7 years are reported by both, from 2017 to 2024.
- How do Malaysia and Yemen rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Malaysia ranks 22nd and Yemen ranks 20th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.